PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, announced that shareholders approved all proposals put forward by the Board of Directors at the Company’s fifth annual General Meeting on April 8, 2026, with a large majority. The meeting, held at the Chollerhalle in Zug, saw 26,780,855 shares represented, corresponding to 80.85% of the issued registered shares.
All six members of the Board of Directors proposed for re-election were appointed for a term ending at the conclusion of the next annual General Meeting in 2027. Peter Wilden was re-elected as Chair of the Board of Directors, and Philippe Weber and Peter Wilden were each individually re-elected as members of the Remuneration and Nomination Committee for a term ending at the 2027 AGM.
Other approved proposals included the re-election of Statutory Auditors and Independent Proxy, approval of the maximum aggregate compensation for the Board and Executive Committee, and discharge for all board and executive members for their activities in financial year 2025. Shareholders also approved the Management Report, Statutory and Consolidated Financial Statements, and the report on non-financial matters for 2025, as well as the Remuneration Report 2025 in a separate consultative vote.
The minutes of the AGM 2026 will be available within 15 days on the Company’s website. The next annual General Meeting is scheduled for April 7, 2027.
PolyPeptide Group AG is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide-based active pharmaceutical ingredients, supporting customers in pharma and biotech. The company runs a global network of six GMP-certified facilities in Europe, the U.S., and India, and its shares are listed on the SIX Swiss Exchange under the ticker PPGN.
